[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,115,0,25,[9,50,86,115,142,168,196,223,247,271,298,325,347,376,399,432,453,483,504,536,558,594,613,634,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100633272","stem-cell-transplantation-for-participants-with-germline-runx1-associated-blood-cancers-100633272",false,"NCT07524530","Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers","Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies","* INCLUSION CRITERIA:\n* Affected participants (Recipients)\n\n  * History of deleterious or suspected deleterious (defined as P\u002FLP or VUS with RUNX1 phenotype) germline RUNX1 mutation as defined by ClinVar (nih.gov)\n  * Histological confirmation of a myeloid malignancy - acute or chronic leukemia (\\\u003C5% marrow blasts preferred) or myelodysplastic syndrome\u002Fmyeloproliferative neoplasms (MDS\u002FMPN) (\\\u003C10% marrow blasts preferred). Participants may be treated on this study to achieve preferred blast cutoffs. Participants with poorly responsive or relapsed disease remain eligible and may proceed as the graft-versus-leukemia (GVL) effect may produce cures.\n\nSubjects requiring standard therapies to prepare for HCT should ideally be referred to this study in remission, if possible. However, sometimes disease status changes during evaluation for HCT and it is necessary to establish disease control through the administration of standard therapies during evaluation for HCT. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the NIH PI, then the subject may receive standard treatment for his\u002Fher underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he\u002Fshe must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol.\n\n* Availability of a haploidentical donor (HLA-match only).\n* Age \\>= 4 and \\\u003C= 70 years\n* Karnofsky (\\>=16 years) or Lansky (\\\u003C16 years) \\>=60%\n* For human immunodeficiency virus (HIV)-infected participants, participant must be on effective anti-retroviral therapy, without uncontrolled opportunistic infection and have approval via Transplant Infectious Disease consultation. Consider donor with CCR5(delta)32 homozygosity for these participants.\n* For individuals with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load (VL) must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV VL.\n* Contraception as follows:\n\n  ---Women of child-bearing potential (WOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \\[IUD\\], abstinence, surgical sterilization) at the study entry and up to and 12 months post conditioning and\u002For post-transplant.\n* Men that can father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and up to 12 months posttransplant or 4 months after conditioning if transplant is not done. We also will recommend men that can father children with partners that can bear children ask their partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Men that can father children must not freeze or donate sperm within the same period.\n* Breastfeeding participants must be willing to discontinue breastfeeding during the study and for 12 months post-transplant or 1 week after conditioning if transplant is not done.\n* Willingness to remain in the NIH hospital or, if discharged, stay close to the NIH (30 minutes drive), for a minimum of 100 days after transplant or longer if there are complications. The participants must commit to having an adult caregiver with them during the first 100 days after the transplant\n* Participants or parent\u002Fguardian\u002Flegally authorized representative must be able to understand and willing to sign a written informed consent document.\n* Additional criteria for recipients suitable for MAC\n\n  * Age \\\u003C= 65 years\n  * HCT-CI \\\u003C4\n  * Pulmonary function tests (PFTs): Forced expiratory volume in the first second (FEV1) and adjusted diffusion capacity of carbon monoxide (DLCO) \\>=66%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest.\n  * Left ventricular ejection fraction (LVEF) \\>=50% by echocardiogram (ECHO) or Multigated Acquisition (MUGA) scan (101)\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C1.5 x institutional upper limit of normal (iULN) (unless Gilbert disease, hemolysis)\n    * Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) \\\u003C=2.5 x iULN (unless therapy related and will improve in discussion with the National Institute of Diabetes and Digestive and Kidney Diseases \\[NIDDK\\])\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=60 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n* Additional criteria for recipients suitable for RIC\n\n  * Age \\\u003C=70 years\n  * PFTs: FEV1 and DLCO \\>=50%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest\n  * LVEF \\>=40% by ECHO or MUGA obtained within 2 months of HSCT (Children s Oncology Group \\[COG\\] criteria).\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C2.5 x iULN (unless Gilbert disease, hemolysis)\n    * AST\u002FALT \\\u003C3.5 x iULN (unless therapy related and will improve in discussion with NIDDK)\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=50 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the CKD-EPI equation)\n* Unaffected participants\n\n  * Haploidentical donors\n\n    ----Age \\>=4 years\n  * Participants or parent\u002Fguardian must be able to understand and willing to sign a written informed consent document.\n  * Unaffected family members\n\n    * Age \\>=18 years\n    * If the participant is a blood relative of the recipient, participant must be negative for RUNX1 mutations by molecular testing\n    * Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-All participants\n\n* Recipients who are receiving any investigational agent except virus specific T cells (VST)\n* Active non-hematologic malignancies\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in study.\n* Participants with the following cardiac conditions: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (except atrial fibrillation if cleared by cardiology consultation)\n* Participants without access to medical care at home.\n* Positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test at screening\n* Uncontrolled intercurrent illness evaluated by history, physical exam, and laboratory studies or situations that would limit compliance with study requirements, interpretation of results or that could increase risk to the participant","ALL","4 Years","70 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Background:\n\nSome blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with. Stem cell transplants are used to treat many diseases including blood cancers. Stem cell transplantation for patients with germline RUNX1 mutation driven blood cancers is standard of care and available in most major medical centers. The difference with this transplantation protocol is that it is prospective, only available to participants with germline RUNX1 variants and designed to determine the extent to which tailoring chemotherapy and supportive care medication doses for each individual patient may improve outcomes compared to data derived from retrospective transplantation protocols for patients with RUNX1 varinats which is less accurate.\n\nObjective:\n\nThe primary objective of this protocol is to determine how tailored doses of chemotherapy and supportive care medications may improve disease free survival as compared to historical\u002Fexpected disease free survival.\n\nEligibility:\n\nPeople aged 4 to 70 years with blood cancer caused by a RUNX1 gene mutation. Other participants are also needed: (1) stem cell donors; (2) relatives who do not have a mutation in the RUNX1 gene; and (3) healthy volunteers.\n\nDesign:\n\nParticipants with blood cancer will be screened during approximately 1-3 months before transplatation. They will have blood tests and tests of their heart and lung function. A sample of bone marrow may be taken.\n\nA flexible tube (central line) will be inserted into a vein in participants chest or lower neck. This line will remain in place during the hospitalization and be used to draw blood and administer drugs. These lines are almost always transitioned to a peripherally inserted central catheter (PICC) line at the time of hospital discharge.\n\nParticipants will be inpatient for 4 to 5 weeks. They will receive drugs to prepare their body for the stem cell transplant. Some may also receive radiation treatment. Other tests will include imaging scans. The stem cell transplant will be given through the central line.\n\nAfter discharge from the clinic, participants will have follow-up visits at least once per week for approximately 100 days. Then they will have follow-up clinic visits for 3 years.\n\nDonors, relatives, and healthy volunteers may provide samples of blood, stool, and saliva. Adults may also opt to provide samples of skin and bone marrow.",[28,29,30,31],"Core Binding Factor Alpha Subunits","Hematologic Neoplasms","Leukemia","Lymphoma",[33,34,35,36],"RUNX1","Haploidentical Hematopoietic Stem Cell Transplant","Germline RUNX1","germline RUNX1-aassociated myeloid malignancy","NOT_YET_RECRUITING","2026-08-20",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":22},"2026-08-26",{"date":45,"type":22},"2036-06-01",{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100516228","phase-1-safety-and-tolerability-of-ziftomenib-combinations-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-100516228","NCT06001788","Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed\u002FRefractory Acute Myeloid Leukemia","Key Inclusion Criteria:\n\n* Has been diagnosed with relapsed\u002Frefractory AML.\n* Has a documented NPM1 mutation or KMT2A rearrangement.\n* Has a documented FLT3 mutation (cA-3 only).\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2.\n* Has adequate hepatic and renal function as defined per protocol.\n* Has an ejection fraction above a protocol defined limit.\n* Participant, or legally authorized representative, must be able to understand and provide written informed consent prior to the first screening procedure.\n* Has agreed to use contraception as defined per protocol.\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of acute promyelocytic leukemia or blast chronic myeloid leukemia.\n* Has clinically active central nervous system leukemia.\n* Has an active and uncontrolled infection.\n* Has a mean corrected QT interval (QTcF) \\> 480ms.\n* Has uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.\n* Has received radiation, chemotherapy, immunotherapy, or any other anticancer therapy including investigational therapy \\\u003C14 days or within 5 drug half-lives prior to the first dose of study intervention.\n* Has had major surgery within 4 weeks prior to the first dose of study intervention.\n* Has received a hematopoietic stem cell transplant (HSCT) and has not previously had adequate recovery per protocol defined criteria.\n* Has active graft-versus-host disease (GvHD) and or on immunosuppressive drugs for the treatment of GvHD\n* Participant is pregnant or lactating.","18 Years",{"count":59,"type":22},171,[61],"PHASE1","The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed\u002Frefractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.",[64,65,66,67,68,69,30,70,71,72,73,74],"AML","AML With Mutated NPM1","Hematologic Malignancy","KMT2Ar","NPM1 Mutation","MLL Rearrangement","Acute Myeloid Leukemia","Leukemia, Myeloid","Leukemia, Myeloid, Acute","Acute Leukemia","Neoplasms by Histologic Type","RECRUITING","2026-08-19",{"date":38,"type":41},{"date":79,"type":41},"2024-02-22",{"date":81,"type":22},"2027-08",{"name":83,"class":84},"Kura Oncology, Inc.","INDUSTRY",45,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":49},"100431492","improving-cognitive-function-in-older-adults-undergoing-stem-cell-transplant-100431492","NCT04898790","Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant","Promoting Physical Activity to Improve Cognitive Function in Older Adults Undergoing Hematopoietic Cell Transplantation","PROACTIVE","Arm 1:\n\nInclusion Criteria for Participants:\n\n* age 60 years and older\n* have a diagnosis of hematological malignancy\n* have received autologous or allogeneic HCT within the prior 3-6 months\n* able to speak and read English\n* have provided written informed consent\n\nExclusion Criteria for Participants:\n\n* there are no exclusion criteria\n\nInclusion Criteria for Participants' Care-Partner:\n\n* age 19 years and older\n* able to speak and read English\n\nExclusion Criteria for Participants' Care-Partner:\n\n* there are no exclusion criteria\n\nInclusion Criteria for Transplant Team Member:\n\n* age 19 years and older\n* able to speak and read English\n\nExclusion Criteria for Transplant Team Member:\n\n* there are no exclusion criteria\n\nArms 2 and 3:\n\nInclusion Criteria for Participants:\n\n* age 55 years and older\n* have a diagnosis of hematological malignancy\n* planned to receive an autologous or allogeneic HCT\n* able to walk 4 meters as part of the Short Physical Performance Battery (with or without assistance)\n* (In Arm 3 only): willingness to be randomized to either initiate the physical activity intervention pre-HCT or following Day 180 post-HCT, and to follow the protocol for the group to which they have been assigned\n* able to speak and read English\n* have provided written informed consent\n\nExclusion Criteria for Participants:\n\n* development of chest pain, severe shortness of breath, or occurrence of other safety concerns during the physical performance measures (i.e. Short Physical Performance Battery)\n* is not cleared to participate in exercise by a physician\n\nIndividuals with the following current conditions\u002Fdiagnoses documented in medical history will be required to provide clearance for exercise from their cardiologist:\n\n* Myocardial infarctions in the past 3 months\n* Resting or unstable angina\n* Uncontrolled and\u002For serious arrhythmias\n* 3rd degree heart block\n* Acute congestive heart failure or ejection fraction \\\u003C30%\n* Clinically significant aortic stenosis\n\nIndividuals with the following conditions\u002Fdiagnoses will be required to provide clearance for exercise from their surgeon:\n\n* Hip fracture, hip or knee replacement, or spinal surgery in the past 3 months\n\n  * other medical, psychiatric, or behavioral factors that in the judgement of the principal investigator may interfere with study participation or the ability to follow either the intervention or the active control condition\n  * (In Arm 3 for those who agree to the voluntary measures of blood, saliva and MRI, there are additional exclusions to avoid conditions that may confound study outcomes):\n* history of residual brain abnormalities from prior severe traumatic brain injury (e.g. encephalomalacia) or other significant abnormalities documented on a recent brain MRI (e.g. brain cancer, large vessel strokes, residual subdural hematoma)\n* history of major stroke with obvious residual deficits\n* history of relapsing and remitting Multiple Sclerosis\n* active moderate to severe psychiatric symptoms due to primary psychiatric disorder\n\nInclusion Criteria for Participants' Care-Partner:\n\n* age 19 years and older\n* able to speak and read English\n* able to walk 4 meters as part of the Short Physical Performance Battery (with or without assistance)\n* have no medical contraindications for participating in light to moderate-intensity physical activity per PI review of medical history as reported on the care-partner medical history form\n\nExclusion Criteria for Participants' Care-Partner:\n\n* development of chest pain, severe shortness of breath, or occurrence of other safety concerns during the physical performance measures (i.e. Short Physical Performance Battery)\n* is not cleared to participate in exercise by a physician\n\nIndividuals with the following current conditions\u002Fdiagnoses documented in medical history will be required to provide clearance for exercise from their cardiologist:\n\n* Myocardial infarctions in the past 3 months\n* Resting or unstable angina\n* Uncontrolled and\u002For serious arrhythmias\n* 3rd degree heart block\n* Acute congestive heart failure or ejection fraction \\\u003C30%\n* Clinically significant aortic stenosis\n\nIndividuals with the following conditions\u002Fdiagnoses will be required to provide clearance for exercise from their surgeon:\n\no Hip fracture, hip or knee replacement, or spinal surgery in the past 3 months\n\n* other medical, psychiatric, or behavioral factors that in the judgement of the principal investigator may interfere with study participation or the ability to follow either the intervention or the active control condition\n\nInclusion Criteria for Transplant Team Member:\n\n* age 19 years and older\n* able to speak and read English\n\nExclusion Criteria for Transplant Team Member:\n\n* there are no exclusion criteria","19 Years",{"count":96,"type":22},114,[98],"NA","Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's Dementia (AD) and the hematological malignancies leading to HCT. There are shared mechanisms and interactions between AD and cancer-related cognitive decline (CRCD). Physical activity improves cognitive function in older adults and survivors of other cancers. This study hypothesizes that increasing physical activity can also improve cognitive function in this vulnerable population.\n\nThe study has two goals. The first is to adapt and test an evidence-based physical activity intervention, The Community Health Activities Model Program for Seniors II (CHAMPS II), in the HCT setting for adults 55 years and older. This will be done using semi-structured interview of up to 10 patients who have experienced the HCT process within the last 3 to 6 months with HCT care-team partners.\n\nThe second goal will explore the prevalence and impact of AD-neuropathology and inflammation on cancer-related cognitive decline (CRCD) in older adults undergoing HCT.",[30,31,101,102,103],"Multiple Myeloma","Myelodysplastic Syndromes (MDS)","Myeloproliferative Neoplasm",[105],"Hematopoietic cell transplantation","2026-08-17",{"date":76,"type":41},{"date":109,"type":41},"2021-11-18",{"date":111,"type":22},"2027-07",{"name":113,"class":114},"University of Nebraska","OTHER",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100457545","cognitive-aftereffects-of-neurotoxicity-in-children-and-young-adults-with-relapsedrefractory-hematologic-malignancies-who-receive-car-t-cell-therapy-100457545","NCT05237986","Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed\u002FRefractory Hematologic Malignancies Who Receive CAR T-cell Therapy","Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed\u002FRefractory Hematologic Malignancies Who Receive CAR T-cell Therapy","* INCLUSION CRITERIA:\n* Participants with disease\n\n  * Participants are diagnosed with relapsed\u002Frefractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites\n  * For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed.\n  * Age \\>= 5 and \\\u003C=35 years old\n  * Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study\n  * Participants (\\\u003C18 years, or \\>=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations\n  * Participant must be able to speak and understand English or Spanish\n  * Participants must have access to a computer or tablet with a camera and an internet connection\n  * Participant or parent\u002Fguardian must be able to understand and willing to sign a written consent document\n* Caregivers (informants)\n\n  * Participants must be able to speak and read in English or Spanish\n  * Participants who are caregivers for participants with disease addressed above\n  * Age \\>= 18 years old\n  * Participants must have access to a computer or tablet\n  * Participants (of children \\\u003C18 years, or \\>18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations\n  * Participant is able to understand and willing to sign a written consent document\n\nEXCLUSION CRITERIA:\n\n-Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)",true,"5 Years",{"count":125,"type":22},60,"OBSERVATIONAL","Background:\n\nCAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills.\n\nObjective:\n\nTo learn if CAR T-cell therapy can affect how children and adults think, process, and remember things.\n\nEligibility:\n\nPeople aged 5-35 who have blood cancer that has not responded to treatment, or the blood cancer has come back after treatment, and who will receive CAR T-cell therapy. Caregivers are also needed. All participants must be able to speak and read in English or Spanish.\n\nDesign:\n\nParticipants will be screened with a medical history.\n\nInformation from participants medical records will be collected.\n\nParticipants will take tests at home or at NIH to see how well they think, read, learn, remember, reason, and pay attention. The tests will be both computerized and paper\u002Fpencil. They will take less than 1 hour to complete.\n\nParticipants and a parent\u002Fadult observer will complete a 5-minute Background Information Form and a checklist of nervous system symptoms.\n\nIf participants are 5 years or older, they will participate in activities to test their ability to do different thinking tasks, like answer questions, complete puzzle patterns, and remember things.\n\nParticipants and their caregivers will complete questions to see if they are having specific symptoms related to receiving CAR T-cells. The questions will assess their well-being and needs. The questions will take less than 1 hour to complete.\n\nSome tests and questions will be repeated at different time points in the study.\n\nParticipation will last for up to 3 years....",[31,30],[130,131,30,31,132],"Cogstate","Memory","Natural History","2026-08-15",{"date":135,"type":41},"2026-08-18",{"date":137,"type":41},"2025-06-23",{"date":139,"type":22},"2028-12-01",{"name":47,"class":48},3,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":49},"100610438","phase-2-all-backbone-in-ayas-100610438","NCT07227584","ALL Backbone in AYAs","Treatment of Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYAs)","Inclusion Criteria:\n\n3.1.1Confirmed diagnosis of Philadelphia chromosome-negative acute lymphoblastic leukemia.\n\n* Diagnosis should be made by peripheral blood, bone marrow aspirate, bone marrow biopsy, or tissue biopsy demonstrating ≥25% involvement by lymphoblasts, with flow cytometry or immunohistochemistry confirming B-ALL or T-ALL.\n\n  o Participants with B-cell and T-cell lymphoblastic lymphoma are eligible regardless of bone marrow involvement Participants with mixed phenotype acute leukemia (MPAL) ARE eligible, if an ALL regimen is felt to be most appropriate treatment.\n* Participants with CNS leukemia ARE eligible. 3.1.2 Allowed prior therapy:\n* Corticosteroids, hydroxyurea, all-trans retinoic acid (ATRA).\n* IT chemotherapy.\n* Emergent radiation therapy or leukapheresis for life threatening complications.\n* One cycle of prior chemotherapy (i.e. an induction cycle given at another institution and participant transfers care for post-induction treatment; OR a participant does not meet eligibility prior to induction but does meet eligibility after remission induction).\n\n3.1.3 Age 18.00 - 50.99 years 3.1.4 Direct bilirubin \\\u003C1.4 mg\u002FdL (total bilirubin \\\u003C 1.4 mg\u002FdL is acceptable). 3.1.5 Willingness to use effective means of birth control. The effects of chemotherapy on the developing human fetus are unknown. For this reason and because therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study.\n\n3.1.6 Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPhiladelphia chromosome-positive \u002F BCR::ABL1 fusion 3.2.2 Participants with mature B-cell (Burkitt's) ALL. Mature B-cell ALL is defined by the presence of surface immunoglobulin AND any of the following: t(8;14)(q24;q32), t(8;22), t(2;8), or c-myc-gene rearrangement by FISH, PCR or other testing. \\[FISH\u002FPCR testing for c-myc rearrangements is not required prior to study entry, but it is suggested for participants with surface immunoglobulin expression or L3 morphology\\]. 3.2.3 Participants with acute undifferentiated leukemia. 3.2.4 Participants receiving any other investigational agent for this condition.\n\n3.2.5 Uncontrolled intercurrent illness including but not limited to ongoing infection with vital sign instability (hypotension, respiratory insufficiency), life-threatening acute tumor lysis syndrome (e.g., with renal failure), symptomatic congestive heart failure, cardiac arrhythmia, intracranial or other uncontrolled bleeding. Circumstances that may significantly interfere with a participant's ability to safely comply with study procedures, such as attend scheduled study visits, adhere to treatment protocols, or complete study assessments. These include a lack of reliable transportation, unstable housing, or psychiatric illness, but reasonable attempts should be made to overcome these circumstances, including but not limited to identifying sponsor, institutional, or thirdparty financial or social support as well as psychiatric consultation for objective assessment. 3.2.6 Sexually active participants of reproductive potential who have not agreed to use an effective contraceptive method for the duration of study participation are ineligible.\n\n3.2.7 Pregnant women are excluded from this study because many of the agents used on this protocol have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these chemotherapy agents, breastfeeding should be discontinued if the mother is enrolled.","51 Years",{"count":151,"type":22},67,[25],"The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs).\n\nThe names of the study drugs involved in this study are:\n\n* blinatumomab (a type of immunotherapy drug)\n* cyclophosphamide (a type of chemotherapy drug)\n* cytarabine (a type of antineoplastic agent)\n* dexamethasone (a type of synthetic glucocorticoid)\n* doxorubicin (a type of antineoplastic agent)\n* etoposide (a type of antineoplastic agent)\n* mercaptopurine (a type of antineoplastic agent)\n* methotrexate (a type of chemotherapy drug)\n* pegaspargase (a type of antineoplastic agent)\n* vincristine (a type of antineoplastic agent)",[155,156,157,30],"Acute Lymphoblastic Leukemia","Philadelphia Chromosome-Negative Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia (ALL)",[155,159,157,30],"Philadelphia Chromosome-Negative lymphoblastic leukemia","2026-08-14",{"date":106,"type":41},{"date":163,"type":41},"2026-04-03",{"date":165,"type":22},"2035-07-31",{"name":167,"class":114},"Dana-Farber Cancer Institute",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100649882","efficacy-of-seated-exercise-on-functional-capacity-and-quality-of-life-in-patients-with-leukemia-during-chemotherapy-cycles-100649882","NCT07740174","Efficacy of Seated Exercise on Functional Capacity and Quality of Life in Patients With Leukemia During Chemotherapy Cycles","Inclusion Criteria:\n\n1. Male patients with age ranges from 30 to 40 years.\n2. All patients in this study will be on chemotherapy from at least one cycle as a treatment of leukemia.\n3. All patients will be hemodynamically stable.\n4. Patients are ambulant.\n\nExclusion Criteria:\n\n1. Lung cancer\n2. History of any pulmonary disease.\n3. Metastasis of lung , ribs and mediastinal structure.\n4. Pulmonary pathology (e.g. acute respiratory distress syndrome, or exacerbation of chronic obstructive pulmonary disease).\n5. Ruptured eardrum or any other condition of the ear.\n6. Severe bronchospasm.\n7. High peak air way pressure (barotraumas).\n8. patients with marked elevated left ventricular end- diastolic volume and pressure.\n9. patients with worsening haert failure signs and symptoms.","MALE","30 Years","40 Years",{"count":178,"type":22},30,[98],"This study aims to evaluate the efficacy of seated exercise on functional capacity and quality of life in patients with leukemia during chemotherapy cycles Participants will receive efficacy of seated exercise on functional capacity and quality of life in patients with leukemia during chemotherapy cycles over a defined period. Outcomes will be assessed using Pulmonary function test, 6 min walk test and FACT- G questionnaire to determine improvements in quality of life in cancer patient rehabilitation special to diagnosed with leukemia.",[30],[183,184,185,186,187],"seated exercise","Functional capacity","Quality of life","Chemotherapy","Exercise therapy","2026-08-13",{"date":106,"type":41},{"date":191,"type":22},"2026-08-01",{"date":193,"type":22},"2026-12-01",{"name":195,"class":114},"Suez University",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":49},"100538863","discovery-evaluating-a-decision-support-tool-for-adults-seen-in-hematologyoncology-clinics-100538863","NCT06296368","DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology\u002FOncology Clinics","DISCOVERY","Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n1. Written or verbal informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information.\n2. Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n3. Age ≥ 60 years at the time of consent.\n4. New patient to either the hematologic malignancies clinic or the bone marrow transplant\u002Fcellular therapy clinic.\n\nExclusion Criteria\n\nAll subjects meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:\n\n1\\. Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the intervention.","60 Years",{"count":205,"type":22},500,[98],"The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.",[209,31,101,30,210],"Hematologic Malignancies","Blood Cancers",[212,213,214],"decision support tool","pragmatic study","best-worst scaling","2026-08-12",{"date":160,"type":41},{"date":218,"type":41},"2024-06-21",{"date":220,"type":22},"2028-09-01",{"name":222,"class":114},"UNC Lineberger Comprehensive Cancer Center",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":122,"sex":17,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100492397","molecular-profiling-for-pediatric-and-young-adult-cancer-treatment-stratification-2-100492397","NCT05691608","MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2","MAPPYACTS2","Inclusion Criteria:\n\n* Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written consent for FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent signed\n* Written informed consent for MAPPYACTS 2 (or non-opposition for retrospective clinical data collection) according to local or national regulations\n* Patient with confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial at the time of tumor sequencing\n* Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (possibly within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease\n* Patients aged ≤ 25 years at the time of initial diagnosis\n* Performance status and life expectancy \\> 3 months at the time of tumor sequencing that allows enrolment into an experimental trial\n* Patients affiliated with a Social Security Regimen or beneficiary of the same as per local regulatory requirements\n\nExclusion Criteria:\n\n* Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results\n* Pregnant women","6 Years","25 Years",{"count":233,"type":22},1800,[98],"FMG2025 continues the previous efforts to propose treatment for patients based on the molecular characteristics of their tumor at treatment failure in cancer precision medicine trials within standard of care in France. However, whereas FMG2025 is a descriptive effort providing the basis for clinical decisions, MAPPYACTS 2 will translate these findings to clinical actions. The symbiosis is critical to advance patient care.\n\nSince 2012, the molecular profiling trials \"MOlecular Screening for CAncer Treatment Optimization\" (MOSCATO-01) and \"MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification\" (MAPPYACTS) have included pediatric and adolescent patients with recurrent or refractory malignancy that underwent on-purpose biopsy or surgical intervention. Whole Exome Sequencing of tumor and normal tissue and RNA Sequencing of tumor tissue have been applied to detect genomic alterations that could lead to an adapted targeted treatment. Furthermore, ancillary studies were associated exploring circulating tumor DNA, the immune contexture of tumors and developing Patient-Derived Xenografts (PDX).\n\nThe FMG2025 project transfers the molecular profiling of advanced pediatric cancers into a global approach that is now considered standard of care in France. Subsequent clinical recommendations and decisions will be made based on discussions with biologists, scientist and physicians in the molecular and clinical molecular tumor boards. Associated ancillary research studies and links to clinical interventional studies remain essential elements of the program to provide clinical, translational and basic research in order to improve scientific knowledge.\n\nThe program is articulated in two main parts that are closely interacting:\n\nFMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent international projects that cover the sequencing of tumor and blood samples and provide molecular reports.\n\nThe clinical study MAPPYACTS 2 that provides clinical and therapeutic discussions of the sequencing results and therapy recommendations via the clinical molecular tumor board (CMTB) reports. It collects molecular and comprehensive clinical data of the patients registered in FMG2025 or equivalent international projects and thereby constitutes the critical link to clinical interventional studies and its sponsors ensuring facilitated access to these trials. It also covers and coordinates ancillary research studies.\n\nDue to the delay in opening of the MAPPYACTS 2 trial, clinical and molecular data for patients whose tumors were sequenced within FMG2025 or equivalent and not included in MAPPYACTS 2 before CMTB or equivalent, will be collected retrospectively after a specific patient\u002Flegal representative information and will contribute to the endpoints of the trial as adequate.",[237,30],"Solid Tumor","2026-08-11",{"date":188,"type":41},{"date":241,"type":41},"2022-09-09",{"date":243,"type":22},"2030-09-09",{"name":245,"class":114},"Gustave Roussy, Cancer Campus, Grand Paris",29,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":270},"100536281","rat-hemato--return-to-work-after-malignant-hemopathy-100536281","NCT06262789","RAT-HEMATO : Return to Work After Malignant Hemopathy","RAT-HEMATO","Inclusion Criteria :\n\n* Patient with hematological malignancy controlled after treatment\n* Induction\u002Fconsolidation chemotherapy completed (excluding maintenance therapy)\n* Patient aged 18 to 55\n* Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy\n* Patient who has not yet returned to work since diagnosis of hematological malignancy\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patient choosing not to return to work\n* Patient not affiliated to a social security system\n* Patient with legal guardian or legal trustee\n* Patient not understanding French\n* Patient with severe cognitive impairment at diagnosis, incompatible with the study","55 Years",{"count":256,"type":22},264,[98],"Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their \"pre-cancer life\" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of \"return-to-work self-efficacy\" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and\u002For beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.",[30,31,101],"2026-08-06",{"date":262,"type":41},"2026-08-10",{"date":264,"type":41},"2024-09-27",{"date":266,"type":22},"2027-09",{"name":268,"class":269},"University Hospital, Angers","OTHER_GOV",9,{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100368437","phase-1-a-study-in-leukemia-patients-with-karonudib-100368437","NCT04077307","A Study in Leukemia Patients With Karonudib","A Phase 1 Study in Patients With Hematological Malignancies to Evaluate Safety, Tolerability and Efficacy of Karonudib","MAATEO","Inclusion Criteria:\n\n1. Written informed consent.\n2. Age 18-75 years (may be extended to older if deemed fit).\n3. The patient has received standard of care treatments and has refractory or relapsed or progressive disease with no suitable standard of care options available.\n\n   For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.\n\n   Cohorts I-IV: AML, ALL, DLBCL, Burkitt lymphoma, multiple myeloma or high-risk MDS, according to the WHO 2016 criteria.\n4. Expansion cohort (Cohort V): Relapsed, Recurrent or Progressive AML or MDS according to the ELN 2017 criteriaWHO 2016 criteria.\n5. For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.\n6. The patient has received standard of care treatments and has refractory or relapsed disease with only experimental therapies as further treatment options.\n7. Life expectancy of at least 8 weeks (as per investigators clinical assessment).\n8. ECOG PFS 0-2\n9. Patients must have measurable disease by blood or bone marrow or imaging examination.\n10. Have a normal left ventricular ejection fraction (LVEF) based on institutional ranges.\n11. Adequate hepatic and renal function defined as:\n\n    1. Total bilirubin \\\u003C 3 x ULN (does not apply to patients with Gilberts Syndrome).\n    2. AST and ALT ≤ 5 x ULN.\n    3. The calculated GFR is at least 30 ml\u002Fmin using Cockcroft-Gault method.\n12. Platelet count≥10 x 109\u002FL. (Can be supported by platelet transfusion)\n13. Subject must be able to take oral medication.\n14. Negative pregnancy test according to CTFG guidance 2014 for females of child-producing potential.\n\nExclusion Criteria:\n\n1. Age less than 18 years.\n2. Less than 4 weeks since stopping previous systemic chemotherapy treatment with the exception of stable dose Hydroxyurea, Trophosphamide, oral Cyclophosphamide, ImID or Thioguanine which needs to be stopped 10 x t1\u002F2 prior to Karonudib administration.\n3. Less than 1 week since stopping palliative radiotherapy.\n4. Less than 2 weeks after surgery except access surgical procedures.\n5. Less than 6 months since a clinically significant cardiovascular event such as myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke or TIA.\n6. Congestive heart failure NYHA class \\> II.\n7. History of arrhythmias or arrhythmias discovered during the screening period (apart from atrial fibrillation without ventricular tachycardia and premature extra beats).\n8. Patients requiring anti-arrhythmic drugs except for stable dose beta-blocking or calcium channel blocking agents.\n9. QTc interval \\>470 ms at baseline (Fridericia correction).\n10. Use of Fentanyl (must be stopped at least 1 week prior to initiation of Karonudib).\n11. Use of anti-oxidants vitamins and Acetylcysteine (must be stopped within 48 hours of starting treatment with Karonudib).\n12. Use of antidepressant medications which are substrate for CYP2D6 (must be stopped at least 3 weeks prior to starting treatment with Karonudib).\n13. Any severe acute or chronic medical condition that places the patient at increased risk or interferes with the interpretation of study results.\n14. Intracerebral engagement (patient with previously known engagement are eligible provided that there is no evidence of disease progression for a minimum of 8 weeks prior to inclusion.\n15. Known acute or chronic infection with hepatitis B or C except for DNA-negative hepatitis B with stable dose anti-viral agents.\n16. Known HIV infection.\n17. Pregnant or breast-feeding women.\n18. Patients with reproductive potential not implementing accepted and effective means of contraception.\n19. Participation in any other clinical trial with a pharmaceutical product within 5 x t½, or minimum 1 week, since last dosing of the IMP, whichever is the shorter.\n20. Acute promyelocytic leukemia (AML M3).\n21. Uncontrolled ongoing systemic or localized infection.\n22. Unable to comply with study procedures.\n23. Peripheral neurological toxicity CTCAE grade 2 or higher.","75 Years",{"count":281,"type":22},50,[61],"The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.\n\nSecondary objectives are to determine a recommended RP2D and schedule for further development of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of treatment efficacy. Overall survival will also be recorded.",[30],[64,17,286,287,288],"MDS","Multiple myeloma","B cell lymphoma","2026-08-04",{"date":260,"type":41},{"date":292,"type":41},"2019-12-03",{"date":294,"type":22},"2027-04-30",{"name":296,"class":114},"Thomas Helleday Foundation",7,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":49},"100584913","phase-2-comparison-of-atlg-and-atg-for-immune-reconstitution-after-allo-hsct-for-hematologic-malignancy-100584913","NCT06895538","Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy","An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases","Inclusion Criteria:\n\n* 1）Age ≧18 years, gender is not limited;\n* 2）Histologically or cytologically confirmed diagnosis of malignant hematologic diseases;\n* 3\\) First time undergoing allogeneic hematopoietic stem cell transplantation;\n* 4\\) ECOG score 0-2;\n* 5\\) Hepatic and renal function, cardiopulmonary function meet the following requirements.\n\n  * Serum creatinine ≤ 1.5 ULN; ②Left ventricular ejection fraction ≥ 45%;\n\n    * Blood oxygen saturation \\>91%;\n\n      * Total bilirubin ≤ 2 × ULN; ALT and AST ≤ 3 × ULN; for ALT and AST abnormalities due to disease (e.g., liver infiltrates or bile duct obstruction), in the judgment of the investigator, the values may be adjusted to ≤ 5 × ULN;\n* 6\\) Expected survival is longer than 12 weeks;\n* 7\\) The subjects will voluntarily and strictly comply with the requirements of the study protocol and will sign a written informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Prior treatment with ATG, ALG, or ATLG drugs within the past six months;\n* 2\\) Allergic to any component of ATLG or ATG;\n* 3\\) Bacterial, viral, parasitic, or mycobacterial infections not adequately controlled by treatment, i.e., inability to undergo hematopoietic stem cell transplantation due to severe infection.\n\n  4\\) Women who are pregnant or breastfeeding, or participants of childbearing potential who are unwilling or unable to use effective methods of contraception; 5) Participants enrolled in another clinical trial (of any investigational drug or device) within 30 days prior to the subject's baseline visit. (Subjects enrolled in observational studies are eligible to participate).\n\n  6\\) Any other circumstance that, in the judgment of the investigator, may interfere with the conduct of the clinical trial and the determination of the results of the trial.",{"count":306,"type":22},24,[25,308],"PHASE3","Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the \"Beijing Protocol\", the use of granulocyte colony-stimulating factor (G-CSF) in combination with anti-thymocyte globulin (ATG) can achieve \"everyone has a donor\". The use of ATG, however, can interfere with the recovery of immune function after transplantation, increasing the risk of life-threatening complications such as viral infections or graft-versus-host disease. Rabbit anti-human T-lymphocyte immunoglobulin (ATLG) is currently approved for the prevention of organ transplant rejection, which is produced differently from ATG. Previous studies have shown that transplant preconditioning with ATLG is effective in preventing graft-versus-host disease and even reduces the incidence of cytomegalovirus, etc. after transplantation. In this study, we will prospectively apply containing ATLG in a cohort of allogeneic hematopoietic stem cell transplantation for malignant hematologic diseases and dynamically observe the state of immune reconstitution of patients after transplantation. We will also compare it with a matched cohort of conventional combined ATGs during the same period to explore the impact of ATLG on immune reconstitution after transplantation.",[30,286,31],[312,313,314,315],"ATLG","ATG","immune reconstitution","allo-HSCT","2026-08-03",{"date":318,"type":41},"2026-08-05",{"date":320,"type":41},"2025-05-03",{"date":322,"type":22},"2027-02-28",{"name":324,"class":114},"Peking University First Hospital",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":333,"targetDuration":335,"studyType":126,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100276031","gmall-registry-and-collection-of-biomaterial-prospective-data-collection-regarding-diagnosis-treatment-and-outcome-of-adult-acute-lymphoblastic-leukemia-all-patients-and-related-diseases-associated-with-a-prospective-collection-of-biomaterial-100276031","NCT02872987","GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial","Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult ALL Patients and Related Diseases Associated With a Prospective Collection of Biomaterial","GMALLregistry","Inclusion Criteria:\n\n* Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols\n* Other Types of Leukemia (NK Cell Lymphoma\u002FLeukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols\n* Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols\n* Age minimum 18 yrs",{"count":334,"type":22},10000,"15 Years","The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.",[155,30,338],"Non-Hodgkin's Lymphoma",{"date":318,"type":41},{"date":341,"type":4},"2009-02",{"date":343,"type":22},"2035-12",{"name":345,"class":114},"Goethe University",147,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":122,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":49},"100643735","strength-training-exercise-in-pediatric-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-step-all-100643735","NCT07634653","Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)","STEP-ALL","Inclusion Criteria for children:\n\nAll subjects must meet the following criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. OR Written assent and parental\u002Flegal guardian consent.\n* Age \\>= 6 and \\\u003C =21 years at the time of diagnosis.\n* Newly- diagnosed with one of the following diseases: B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\n\nExclusion Criteria for children:\n\n* Subjects must not be receiving any investigational or additional anti-cancer medicines during induction.\n* Significant concurrent disease, illness, or psychiatric disorder or social issue that would compromise subject safety or adherence to the protocol treatment or procedures, interfere with consent, study participation, follow-up, or interpretation of the study results.\n\nOptional caregiver participation:\n\nInclusion Criteria :All caregivers must meet the following criteria\n\n* Written informed consent to participate in the caregiver interviews.\n* The caregiver must be a parent or legal guardian ≥ 18 years old, and their child must be \\\u003C18 years",{"count":355,"type":22},40,[98],"Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment. These can include tiredness, weak muscles, pain, nerve problems, difficulty moving, and other physical challenges. Many children with ALL are also overweight at diagnosis, and weight gain often continues during treatment. As a result, about half of childhood leukemia survivors have a BMI at or above the 85th percentile.\n\nTreatment decisions are usually based on a child's symptoms and genetic risk factors. However, some risk factors such as physical activity can be modified. Exercise during treatment may help children feel better and may even improve survival. However, research on early symptom tracking and structured exercise during the first phase of chemotherapy is limited, uses different methods, and often does not include reliable patient-reported symptoms.\n\nEffective exercise programs for children with ALL and lymphoblastic lymphoma need to consider the child's age, treatment side effects, motivation, family support, and ways to encourage long-term behavior change. Because children spend little time in the hospital during the induction phase, a mix of in-person and virtual sessions supported by real-time Zoom instruction can make it possible to offer safe and supervised exercise at home.\n\nThis study will use a guided exercise plan that includes tools to track sets, repetitions, intensity, warm-up time, and perceived exertion. These tools help with consistent monitoring and support both patients and caregivers throughout the program. Twenty children newly diagnosed with ALL or lymphoblastic lymphoma who receive standard 3-4 drug induction chemotherapy will be invited to participate. Our goal is to determine whether a 9-week hybrid exercise program, combined with weekly symptom check-ins, is practical and achievable in both hospital and home settings.",[30,73,359,360,155],"Acute Lymphoid Leukemia","Lymphoblastic Lymphoma",[362,363,364,365,366,367,368],"children","pediatric","weight gain","body mass index (BMI)","physical activity","Exercise","hybrid exercise program","2026-07-31",{"date":316,"type":41},{"date":372,"type":41},"2026-05-01",{"date":374,"type":22},"2028-06-01",{"name":222,"class":114},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":141},"100589944","mosaic-trial-for-stem-cell-transplant-recipients-100589944","NCT06960993","Mosaic Trial for Stem Cell Transplant Recipients","Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients","Mosaic","Inclusion Criteria:\n\n* Diagnosed with a hematologic cancer according to medical records\n* Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites\n* Aged 18 or older (no upper limit)\n* English or Spanish Proficient\n* Interested in using a website to learn about stem cell transplant\n* Ability to understand and willingness to sign an informed consent document and comply with all study procedures\n\nExclusion Criteria:\n\n* Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms\n* Undergoing the first in a planned tandem stem cell transplant\n* Unable to provide meaningful consent (severe cognitive impairment or language difficulties)",{"count":385,"type":22},356,[98],"The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups).\n\nThe main questions this trial aims to answer are:\n\n1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life?\n2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and\u002For reductions in avoidant coping and perceived stress?\n3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English\u002FSpanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.",[66,389,390,30,31,101,391],"Stem Cell Transplant","Bone Marrow Transplant","Myelodysplastic Syndromes",{"date":316,"type":41},{"date":394,"type":41},"2025-04-28",{"date":396,"type":22},"2030-02-01",{"name":398,"class":114},"Northwestern University",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":407,"maxAge":57,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":4},"100649662","dyadic-physical-activity-intervention-for-children-undergoing-cancer-treatment-100649662","NCT07737418","Dyadic Physical Activity Intervention for Children Undergoing Cancer Treatment","Dyadic-based Physical Activity Intervention for Children Who Are Undergoing Cancer Treatment: A Randomized Controlled Trial","DYAD-PA","Inclusion Criteria:\n\n* Children aged 9-18 years old\n* Diagnosed with leukaemia\n* Currently undergoing maintenance therapy\n* Have a parent willing to participate in the study\n* Both the child and participating parent speak Cantonese and read Chinese\n\nExclusion Criteria:\n\n* Children under palliative care with evidence of cancer recurrence or second malignancies\n* Children with medical contraindications for PA, such as thrombosis, as documented by physicians\n* Children or parents with physical impairment or cognitive and learning problems (identified from medical records)\n* Participants in the team's other interventional studies","9 Years",{"count":409,"type":22},198,[98],"The goal of this study is to learn if a parent-child dyadic physical activity (PA) intervention works to improve physical activity levels in children with leukaemia. It will also learn about the intervention's effects on children's self-confidence in doing physical activity and their quality of life. The main questions it aims to answer are:\n\nDoes the dyadic PA intervention increase the amount of physical activity children do, compared with an individual PA intervention or usual care? Does the dyadic PA intervention improve children's confidence in doing physical activity and their overall quality of life? What is the cost-effectiveness of the dyadic intervention relative to the individual intervention and psychological support control group?\n\nResearchers will compare three groups: children and parents doing physical activity together (dyadic intervention), children doing physical activity individually (individual intervention), and children receiving psychological support sessions only (control group), to see if involving parents makes a difference.\n\nParticipants will:\n\nAttend weekly sessions for 3 months (12 sessions total) Wear an activity tracker for 7 days and complete questionnaires at 5 different time points over 12 months Some participants will also be invited to take part in an interview about their experience",[30,413],"Physical Inactivity",[30,415,416,417,418,419,420,421,367,422,423],"Physical Activity","Self-Efficacy","Parent-Child Dyad","Quality of Life","Randomized Controlled Trial","Maintenance Therapy","Under treatment","Dyadic intervention","Pediatric oncology","2026-07-30",{"date":369,"type":41},{"date":427,"type":22},"2027-01-01",{"date":429,"type":22},"2030-01-01",{"name":431,"class":114},"The Hong Kong Polytechnic University",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":439,"maxAge":231,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":49},"100488869","phase-2-study-of-pedi-crib-mini-hyper-cvd-with-condensed-rituximab-inotuzumab-ozogamicin-and-blinatumomab-crib-for-relapsed-therapy-for-pediatric-with-b-cell-lineage-acute-lymphocytic-leukemia-100488869","NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","Inclusion Criteria:\n\n* Pediatric, adolescent, or young adult patients with B-ALL as per NCCN v2.2021 and WHO classification in relapse or primary refractory and, either\u002Fboth of the following: • Unable to receive anthracyclines (see section 3.1.8) or is PEG-asparaginase intolerant.\n\n  * For leukemia: Patients must have ≥ 5% blasts expressing CD19 and CD22 in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood.\n  * If patient does not have CD20, they can still be enrolled but will not receive rituximab.\n* Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥ 50% for patients who are \\> 16 years old.\n* Patients with asymptomatic CNS leukemia are eligible (see also Exclusion Criterion 3.2.2.)\n* Age \\> = 1 years of age and less than 25 years of age.\n* The following baseline laboratory data:\n\n  * Total serum bilirubin ≤1.5x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN.\n  * Adequate renal function per age51 unless related to the disease. Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults).\n  * Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement\n* Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and 30 days after the last treatment and 8 months after the last dose of inotuzumab and 12 months after the last dose of rituximab. Effective methods of birth control include:\n\n  * Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin)\n  * Intrauterine devices (IUDs)\n  * Condom or occlusive cap (diaphragm or cervical\u002Fvault caps) used with Spermicide\n  * Abstinence\n* Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment and 5 months after the last dose of inotuzumab.\n* Patients with cardiac disease, include but not limited to: (Left ventricular ejection fraction (EF) \\\u003C 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received \\>450mg\u002Fm2 of doxorubicin and cannot receive anthracyclines.\n\nExclusion Criteria:\n\n* Past or current history of a secondary or other primary tumor or a chronic myeloid leukemia (CML) blast crisis with exception of:\n\n  * Curatively treated non-melanomatous skin cancer\n  * Other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years\n* Presence of clinically significant uncontrolled CNS pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis. Presence of the following are allowed: headaches, vomiting, nerve palsy\n* Medical history of cardiovascular disease such as:\n\n  ° Clinically significant cardiac disease including congestive heart failure (NYHA class III or IV) or arrhythmia or conduction abnormality requiring medication\n* Patients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable.\n* Known active hepatitis B or C infection or known seropositivity for HIV.\n* Patients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse.\n* Active acute\u002Fchronic Graft-versus-Host Disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.\n* If patient has not recovered (as deemed by the investigator) from previous chemotherapy, surgery, radiation before the start of study drugs.\n\n  ° To reduce the circulating blast count or palliation, the following are allowed prior to starting: Single dose intravenous cytarabine, steroids or hydroxyurea. No washout necessary for these agents.\n* Females who are pregnant or lactating.\n* Male or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards.\n* Other severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated Protocol 2022-0312 V3 Dated 11\u002F9\u002F2023 Property of Leukemia at MD Anderson 17 with study participation or investigational product administration or may interfere with the interpretation of study results and\u002For would make the patient inappropriate for enrollment into this study.\n* Patients with Trisomy 21, or bone marrow failure syndromes are not eligible.\n* Prior history of allergic reaction to any of the agents.\n* Patients who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.\n* Patients may be excluded if they are currently enrolled in another ongoing clinical trial with investigational products","1 Year",{"count":441,"type":22},27,[25],"To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.",[30],"2026-07-28",{"date":424,"type":41},{"date":448,"type":41},"2023-07-14",{"date":450,"type":22},"2029-12-31",{"name":452,"class":114},"M.D. Anderson Cancer Center",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":463,"conditions":464,"keywords":468,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":49},"100621722","weight-gain-in-pediatric-leukemia-survivors-100621722","NCT07374315","Weight Gain in Pediatric Leukemia Survivors","A Family-based Intervention Approach to Address Weight Gain in Pediatric Leukemia Survivors","Patient Eligibility Criteria:\n\n* Must have a diagnosis of ALL (T or B cell).\n* Must be receiving standard of care maintenance chemotherapy or be within 6 months of having concluded maintenance chemotherapy at the time of enrollment.\n* Must be at least 6 years of age and no older than 18 years of age at time of enrollment.\n* Must be able to speak and understand English.\n* Must have a caregiver who is participating in this study.\n* Must be able to perform some level of exercise (e.g., a brisk walk for at least five minutes) as determined by self-report.\n* Must not have severe developmental delay\u002Fintellectual disabilities (such as Trisomy32, severe presentations of autism spectrum disorder) or significant mental illness (such as active suicidal ideation, psychotic symptoms, manic or hypomanic episodes, or severe substance use disorder) that may interfere with ability to participate in modified Family Based Therapy (FBT).\n* Patients 10 and older must have a negative SCOFF screen for disordered eating (Score of 2 or more would disqualify the patient and require discussion with primary team)\n* Must be able to understand and willing to sign an IRB-approved written informed consent document or be able to provide verbal assent along with written consent provided by a legally authorized representative.\n\nCaregiver Eligibility Criteria:\n\n* Self-reported as the primary caregiver of a pediatric patient diagnosed with ALL who is also participating in this study.\n* Must be at least 18 years of age.\n* Must be able to speak and understand English.\n* Must be able to perform some level of exercise (e.g., a brisk walk for at least five minutes) as determined by self-report\n* Must be able to understand willing to sign an Institutional Review Board (IRB)-approved written informed consent document.",{"count":461,"type":22},80,[98],"This is a trial assessing the efficacy of two weight maintenance programs for children with acute lymphoblastic leukemia (ALL) and the patients' caregivers. Patients and their caregivers will be randomized 1:1 to Arm A, a non-intensive educational intervention using National Institute of Health (NIH) Educational Resources (We Can! for children 8-13 and Take Charge of Your Health for teenagers 14-18), or Arm B, a Modified Guided Self-Help Family Intervention for Leukemia patients (mL-GSH). Outcomes will be assessed through activity trackers, obesity biometrics, and nutrition and physical activity assessments.",[30,465,466,467],"Pediatric Acute Lymphoblastic Leukemia","Pediatric Acute Lymphoblastic Leukemia in Remission","Pediatric Obesity",[30,469,470,471,472,473],"Lymphoblastic Leukemia","Weight Management","Late Effects","Health Behaviors","Healthy Habits","2026-07-23",{"date":476,"type":41},"2026-07-24",{"date":478,"type":22},"2026-08-31",{"date":480,"type":22},"2029-05-31",{"name":482,"class":114},"Washington University School of Medicine",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":503},"100527826","phase-1-ciml-nk-cells-with-venetoclax-for-aml-100527826","NCT06152809","CIML NK Cells With Venetoclax for AML","A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AML","Inclusion Criteria for Trial Enrollment (Screening Visit #1):\n\n* Diagnosis of acute myeloid leukemia (AML)\n* Age ≥ 18 years old\n* At time of screening patient is being treated with HMA(azacitidine or decitabine) + venetoclax therapy and has received at least 1 cycle of HMA (azacitidine or decitabine) + venetoclax. Patients can have received other lines of therapy prior to HMA + venetoclax therapy including prior chemotherapy and any prior stem cell transplant, provided that the stem cell transplant is \\> 6 months prior with no ongoing need for immunosuppressive therapy for active graft-versus-host disease.\n* Presence of molecular risk factors for relapse with continued HMA + venetoclax therapy as defined by any of the following present at the time of diagnosis or start of HMA + venetoclax therapy (these do not need to be present at the time the screening BM biopsy):\n\n  * 2022 ELN adverse risk karyotype: t(6;9)(p23.3;q34.1)\u002FDEK::NUP214; t(v;11q23.3)\u002FKMT2A-rearranged; t(9;22)(q34.1;q11.2)\u002FBCR::ABL1; t(8;16)(p11.2;p13.3)\u002FKAT6A::CREBBP; inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)\u002F GATA2, MECOM(EVI1), t(3q26.2;v)\u002FMECOM(EVI1)-rearranged; -5 or del(5q); -7; Complex karyotype, monosomal karyotype\n  * 2022 ELN adverse risk mutations: Any one of the following mutations: Mutated TP53, ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and\u002For ZRSR2\n  * Additional mutations associated with acquired resistance to venetoclax: Mutated NRAS, KRAS, FLT3 ITD\u002FTKD\n* ECOG performance status ≤2 (see Appendix A)\n* Participants must meet the following organ function as defined below:\n\n  * Direct bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * creatinine clearance ≥ 45 mL\u002Fmin; calculated by the Cockcroft Gault formula\n  * oxygen saturation ≥ 90% on room air\n  * left ventricular ejection fraction ≥ 40%\n* Negative pregnancy test for women of childbearing potential only.\n* The effects of CIML NK cells and IL-2 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and until 4 months after the last IL-2 dose administration.\n* Participants with current symptoms of cardiac disease should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)\n* Subjects must be able to swallow pills.\n* No laboratory evidence of ongoing hemolysis in opinion of investigator (demonstration of hemolysis should include a haptoglobin level that is below assay).\n\nExclusion Criteria for Trial Enrollment (Screening visit #1)\n\n* Prior allogeneic stem cell transplant, organ transplant or donor lymphocyte infusion (DLI), CAR-T cell or NK cell therapy\n* Persisting Grade \\> 1 non hematologic toxicity related to prior therapy; however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.\n* Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease disease requiring any steroids \\>\\> the equivalent dose of 10 mg of prednisone or other immunosuppressive therapies at the time of this screening visit (e.g., rheumatoid arthritis, systemic progressive sclerosis \\[scleroderma\\], systemic lupus erythematosus, autoimmune vasculitis \\[e.g., Wegener's Granulomatosis\\]) and motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis). Patients with Hashimoto's thyroiditis are eligible to go on study.\n* Pregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 and with the potential for teratogenic or abortifacient effects by Flu\u002FCy chemotherapy regimen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CIML NK cells and IL-2, breastfeeding should be discontinued if the mother is treated on this study.\n* HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions with anti-retroviral agents used in this study. In addition, these participants are at increased risk of lethal infections when treated with marrow suppressive therapy.\n* Individuals with active uncontrolled hepatitis B or C are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after conditioning therapy.\n* Individuals with a history of a different malignancy are ineligible except for the following circumstances: 1. History of other malignancy and have had complete remission of disease for at least 2 years; 2. Diagnosed and treated within the past 2 years for: nonmetastatic melanoma, surgically resected (not needing systemic chemotherapy) squamous cell carcinoma of skin and nonmetastatic prostate cancer not needing systemic chemotherapy.\n* History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2 or other agents used in study.\n* Participants who are receiving any other investigational agents for this condition\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Prior history of Grade 2 or higher hemolytic anemia (≥ 2g decrease in hemoglobin plus laboratory evidence of hemolysis) from any cause.\n\nInclusion Criteria to Start Investigational Treatment Plan (Screening visit #2)\n\n* Patient was eligible for protocol per section 3.1.\n* Repeat bone marrow biopsy at this time shows a complete remission (CR) or complete remission with incomplete count recovery (CRi) or morphologic leukemia free state (MLFS) (\\\u003C 5% blasts) but with presence of measurable residual disease (MRD+). MRD can be determined by either flow cytometry, next generation sequencing or PCR. Patients with only persistent DNMTA, TET2 or ASXL1 mutations will not qualify as MRD+ as these DTA mutations without other comutations are associated with clonal hematopoiesis. OR\n* Repeat bone marrow biopsy at this time shows 5-19% residual myeloblasts in the bone marrow by either bone marrow aspirate or core biopsy.\n* Confirmed haploidentical or fully HLA-matched related donor that is willing and eligible for non-mobilized collection.\n* ECOG performance status ≤2 (see Appendix A)\n* Participants must meet the following laboratory and organ function as defined below:\n\n  * Direct bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * creatinine clearance ≥ 45 mL\u002Fmin; calculated by the Cockcroft Gault formula\n  * oxygen saturation ≥ 90% on room air\n* No significant change in clinical status that would, in the opinion of the investigator, increase the risk of adverse events associated with CIML NK infusion, (e.g., symptomatic congestive heart failure, unstable angina, cardiac arrhythmia)\n* Negative pregnancy test for women of childbearing potential only.\n* Subjects must be able to swallow pills.\n\nExclusion Criteria to Start Investigational Treatment Plan (Screening visit #2)\n\n* No live vaccines within the last 6 months.\n* No ongoing or active infections.\n* Moderate\u002Fstrong inhibitors of CYP3A except of antifungal medications (such as posaconazole, voriconazole) which the patient is on and the dose of venetoclax has already been adjusted. These are excluded as moderate\u002Fstrong inhibitors of CYP3A induce higher drug levels of venetoclax which in turns carry the risk of CIML NK cell elimination.\n* The presence of donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) \\>1000 using a standard assay in subjects who do not receive a desensitization protocol prior to and during stem cell transplant.\n\nCriteria to Receive Lymphodepletion on Day -5\n\n* Adequate organ function within 24 hours of lymphodepletion as defined below:\n\n  * Direct bilirubin: ≤ 1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST (SGOT)\u002FALT (SGPT): ≤ 3 x institutional ULN\n* No significant change in clinical status that would, in the opinion of the investigator, increase the risk of adverse events associated with lymphodepletion, (e.g., significant hypoxemia, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia)\n* No evidence of active, uncontrolled infection. Patients receiving antibiotics for an infection may be treated if they have clinically responded to antibiotics. These cases should be reviewed with the study PI before proceeding.\n* No live vaccines within the last 6 months\n\nCriteria to Receive CIML NK Infusion\n\n* Adequate organ function within 24 hours of NK cell infusion as defined below:\n\n  * Direct bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * Creatinine clearance ≥ 45 mL\u002Fmin; calculated by the Cockcroft Gault formula\n* No Grade ≥3 non-hematologic toxicities of cyclophosphamide and fludarabine conditioning (except for Grade 3 nausea, vomiting, diarrhea, or constipation).\n* No significant change in clinical status that would, in the opinion of the investigator, increase the risk of adverse events associated with CIML NK infusion, (e.g., significant hypoxemia, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia)\n* No evidence of active, uncontrolled infection. Patients receiving antibiotics for an infection may be treated if they have clinically responded to antibiotics. These cases should be reviewed with the study PI before proceeding.\n* No systemic steroid therapy (oral or IV) of \\> 10mg prednisone or equivalent dose of other steroid agent on the day of NK cell infusion\n\nIf any of the above criteria are noted at these time points, please discuss with PI the benefits\u002Frisks of proceeding with the CIML infusion and document rationale for course of action taken in study regulatory binder. However, patient may still receive CIML NK infusion if relevant parameters are reviewed and both PI and IND holder agree with proceeding.\n\nIf inclusion\u002Fexclusion criteria are not met on planned day of CIML NK cell infusion, the NK cell infusion may be delayed for up to 24 hours to enable inclusion criteria to be met.\n\nCriteria to Receive Venetoclax\n\n* Adequate organ function within 24 hours of venetoclax initiation as defined below:\n\n  * Total bilirubin: ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \\\u003C 3 x ULN)\n  * AST(SGOT)\u002FALT(SGPT): ≤3 x institutional ULN\n  * No Grade ≥3 non-hematologic toxicities of cyclophosphamide and fludarabine conditioning (except for Grade 3 nausea, vomiting, diarrhea, or constipation).\n* No significant change in clinical status that would, in the opinion of the investigator, increase the risk of adverse events associated with venetoclax administration, (e.g., significant hypoxemia, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, severe ongoing tumor lysis syndrome)\n* No evidence of active, uncontrolled infection. Patients receiving antibiotics for an infection may be treated if they have clinically responded to antibiotics. These cases should be reviewed with the study PI before proceeding.\n* No live vaccines within the last 6 months",{"count":491,"type":22},10,[61],"The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML).\n\nNames of the study therapies involved in this study are:\n\n* Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion\n* CIML NK (a cellular therapy)\n* IL-2 (a recombinant, human glycoprotein)\n* Venetoclax (a selective inhibitor of BCL-2 protein)",[70,495,30,71],"Acute Myeloid Leukemia Recurrent",[70,495,30,71],{"date":476,"type":41},{"date":499,"type":41},"2024-02-20",{"date":501,"type":22},"2027-11-30",{"name":167,"class":114},2,{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":439,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":522,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":535},"100357464","phase-1-safety-and-efficacy-of-ponatinib-for-treatment-of-pediatric-recurrent-or-refractory-leukemias-lymphomas-or-solid-tumors-100357464","NCT03934372","Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","An Open-Label, Single-Arm, Phase 1\u002F2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants","Inclusion Criteria:\n\nHistologically or cytologically confirmed diagnosis of the following malignancies:\n\n\\- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, for which standard therapy is not available or is not indicated.\n\n\\- Phase 2, Group A with CP-CML: CP-CML at the time of study entry and must be resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy or be in \"warning\" response status or have the T315I kinase domain mutation.\n\nMust have 1 bone marrow aspirate with documentation of BCR-ABL translocation by conventional cytogenetics, metaphase FISH, or q-PCR performed within 42 days before the first dose of ponatinib.\n\n\\- Phase 2, Group B with other leukemias or solid tumors: ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, with mutations of RET, FLT3, KIT, FGFR, PDGFR, TIE2, VEGFR, or any other mutations where ponatinib may have biological activity (eg, EPH receptors and SRC families of kinases) as assessed on fresh or archived tumor tissue.\n\nParticipants with solid tumors or with lymphoma must have measurable disease by CT or MRI based on RECIST v1.1 or the Lugano lymphoma guidelines as determined by site radiology.\n\nPrior therapies as follows:\n\n\\- Phase 1: Participants with CML who are resistant to or intolerant of (as defined Appendix F) to at least 1 prior BCR-ABL-targeted TKI therapy.\n\nParticipants with ALL who have progressed on or after all available or indicated therapies, which may have included 1 prior BCR-ABL-targeted TKI therapy.\n\nParticipants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).\n\nParticipants with solid tumors (including tumors of the CNS) or lymphomas who have progressed despite standard therapy or for whom no effective standard therapy is available or indicated.\n\n\\- Phase 2, Group A with CP-CML: Participants who are resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy.\n\n\\- Phase 2, Group B with other leukemias or solid tumors: Participants with ALL who have progressed on or after all available or indicated therapies, which must have included 1 prior BCR-ABL-targeted TKI therapy.\n\nParticipants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).\n\nParticipants with solid tumors (including tumors of the CNS) or lymphomas who progressed despite standard therapy or for whom no effective standard therapy is available or indicated.\n\n* Karnofsky performance status ≥ 40% for participants ≥ 16 years old or Lansky Play Scale ≥ 40% for pediatric participants \\\u003C 16 years old.\n* Participants must have recovered to \\\u003C Grade 2 per the NCI CTCAE v5.0 or to baseline from any non-hematologic toxicities (except alopecia) due to previous therapy.\n* Willingness to avoid pregnancy or fathering children.\n\nExclusion Criteria:\n\nPrior therapies:\n\n\\- Participants with BP-CML, ALL, or AML who have received any of the following: Corticosteroids or hydroxyurea within 24 hours before the first dose of ponatinib.\n\nVincristine within 7 days before the first dose of ponatinib. Other chemotherapy (excluding intrathecal chemotherapy) within 14 days before the first dose of ponatinib.\n\n\\- Participants (except the BP-CML, ALL, and AML participants described above) who: Have had cytotoxic chemotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) before the first dose of ponatinib.\n\nPrior radiation therapy or radio-isotope therapy within 6 weeks before the first dose of ponatinib except local radiotherapy for palliative indication within 14 days before the first dose of ponatinib.\n\nAutologous or allogeneic stem cell transplant \\\u003C 3 months before the first dose of ponatinib.\n\nMajor surgery within 14 days before the first dose of ponatinib. Inadequate recovery and\u002For complications from a major surgery before starting therapy.\n\nPrior treatment with any of the following:\n\n* Immunosuppressive therapy (including post stem cell transplant regimens) within 14 days before the first dose of ponatinib.\n* Any targeted cancer therapy (including TKIs) within 7 days before the first dose of ponatinib.\n* Any other investigational anticancer agents within 30 days or 5 half-lives, whichever is longer, before randomization.\n* Any monoclonal antibody-directed anticancer therapy within 5 half-lives of the first dose of ponatinib.\n* Any chimeric antigen receptor therapy within 28 days before the first dose of ponatinib\n* Ponatinib\n* Protocol-defined lab Values\n* Significant concurrent, uncontrolled medical condition, including but not limited to the following:\n* Pancreatic: clinical, radiological, or laboratory evidence of pancreatitis.\n* Cardiac:\n* SF \\\u003C 27% by ECHO, OR EF \\\u003C 50% by MUGA.\n* Abnormal QTcF on screening ECG, defined as QTcF of ≥ 450 ms.\n* Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute MI within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV CHF (see Appendix P), and arrhythmia requiring therapy unless approved by the medical monitor\u002Fsponsor.\n* Uncontrolled hypertension.\n* Currently taking drug(s) that are known to have a risk of causing prolonged QTc or TdP unless the drug(s) can be changed to acceptable alternatives (ie, an alternate class of agents that do not affect the cardiac conduction system), or the participant can safely discontinue the drug(s).\n* Cerebral:\n* Participants with solid tumors with intracranial metastasis OR participants with active CNS leukemia (ie, CNS-2 status \\[\\\u003C 5\u002FμL WBCs and cytospin positive for blasts, or ≥ 5 \u002FμL WBCs but negative by Steinherz\u002FBleyer algorithm (equation used for traumatic lumbar punctures), disseminated leptomeningeal disease, or CNS chloroma.\n* Pre-existing significant CNS pathology including history of severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination\u002Fmovement disorder, or autoimmune disease with CNS involvement.\n* History of cerebrovascular ischemia\u002Fhemorrhage with residual deficits.\n* Note: Participants with a history of cerebrovascular ischemia\u002Fhemorrhage remain eligible provided all neurologic deficits have resolved clinically according to Inclusion Criterion 6.\n* Uncontrolled seizure disorder.\n* Coagulation:\n* Significant bleeding disorder or thrombophilia unrelated to the underlying malignancy indication for study participation.\n* Gastrointestinal:\n* Gastrointestinal disorders, such as malabsorption syndrome or any other illness that could affect oral absorption.\n* Genetic:\n* Participants with DNA fragility syndromes, such as Fanconi anemia and Bloom syndrome.\n* Participants with Down syndrome.\n* Participants with any active ≥ Grade 2 graft versus host disease.\n* Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.\n* Active HBV or HCV infection that requires treatment or at risk for HBV reactivation. Hepatitis B virus DNA and HCV RNA must be undetectable upon testing. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive.\n* Known HIV infection.\n* Current use of prohibited medication (see Section 6.7.2).\n* Known hypersensitivity or severe reaction to ponatinib or excipients of ponatinib.\n* Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.\n* Inability or unlikeliness to comply with the dose schedule and study evaluations, in the opinion of the investigator.\n* Females who are pregnant or lactating.\n* Other exclusions may apply.","17 Years",{"count":513,"type":22},70,[61,25],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \\\u003C 18 years with advanced leukemias, lymphomas, and solid tumors.",[70,517,518,519,155,520,30,31,521],"Accelerated Phase Chronic Myeloid Leukemia","Blast Phase Chronic Myeloid Leukemia","Chronic Phase Chronic Myeloid Leukemia","Acute Lymphocytic Leukemia","Solid Tumors",[30,523,524,525,526],"Solid tumors","Pediatric","Tyrosine kinase inhibitor","lymphomas","2026-07-22",{"date":474,"type":41},{"date":530,"type":41},"2020-01-29",{"date":532,"type":22},"2028-02-01",{"name":534,"class":84},"Incyte Biosciences International Sàrl",23,{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":49},"100401229","early-phase-1-value-of-chemokine-receptor-cxcr4-imaging-for-diagnosis-and-prognostic-evaluation-in-lymphoproliferative-diseases-100401229","NCT04504526","Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases","Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor","80 Years",{"count":281,"type":22},[546],"EARLY_PHASE1","Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET\u002FCT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET\u002FCT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.",[31,101,30],"2026-07-19",{"date":551,"type":41},"2026-07-21",{"date":553,"type":41},"2020-08-07",{"date":555,"type":22},"2027-12-31",{"name":557,"class":114},"First Affiliated Hospital of Fujian Medical University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":122,"sex":17,"minAge":57,"maxAge":565,"enrollmentInfo":566,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":567,"conditions":568,"keywords":574,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":49},"100647771","rutgers-university-study-of-the-genetics-of-blood-cancers-100647771","NCT07714044","Rutgers University Study of the Genetics of Blood Cancers","The Rutgers University Study of the Genetics of Blood Cancers","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* have access to the internet and a computer, laptop, tablet or smartphone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to your home\n* willing to complete a survey with questions about health related to the study of blood cancer.\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criteria","110 Years",{"count":334,"type":22},"The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.",[210,569,30,31,570,571,209,572,573],"Blood Cancer","Myeloma","Hematologic Cancer","Hematologic Neoplasm","Hematologic Tumors",[575,576,577,578,579,580,581,582,583,584],"genetics","blood cancer","blood cancers","leukemia","lymphoma","myeloma","hematologic cancer","hematologic malignancy","hematologic tumor","hematologic neoplasm","2026-07-15",{"date":587,"type":41},"2026-07-20",{"date":589,"type":22},"2026-08",{"date":591,"type":22},"2029-08",{"name":593,"class":114},"Rutgers, The State University of New Jersey",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":122,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":49},"100552147","driving-inclusivity-validity-and-equity-in-research-through-strategic-engagement-diverse-100552147","NCT06469307","Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)","DIVERSE","CAB Participant Inclusion Criteria:\n\n* Age 18 or older\n* English speaking\n* Ability to understand and willingness to provide oral consent\n* DFCI patient who are in remission from a blood cancer \\>1 year will be preferred.\n\nCAB Participant Exclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C18 years old)\n* Prisoners.\n* Unwilling\u002Funable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1\n* Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.\n* Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.\n\nInvestigator Participant Inclusion Criteria:\n\n* Age 18 older\n* English Speaking\n* Site or Principal investigator\n* Not a member of the research team",{"count":355,"type":22},[98],"The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.",[569,30],[569,30],{"date":607,"type":41},"2026-07-16",{"date":609,"type":41},"2024-12-09",{"date":611,"type":22},"2028-01-30",{"name":167,"class":114},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":175,"enrollmentInfo":620,"targetDuration":123,"studyType":126,"phases":4,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":633},"100436866","genomically-profiling-collecting-archiving-and-distributing-hematologic-malignancy-specimens-100436866","NCT04968834","Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens","Protocol For Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens From Children and Young Adults With Hematologic Malignancy","Inclusion Criteria:\n\n* Age: birth to \\\u003C 30 years of age\n* Diagnosis:\n\n  \\-- Patient with acute leukemia, chronic leukemia, MDS\u002FAML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed\u002Frefractory.\n* Pathology Criteria:\n\n  \\-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence\n* Specimen Criteria:\n\n  * Sufficient sample available for genomic profiling OR bone marrow aspirate\u002Fblood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)\n\nExclusion Criteria:\n\n\\- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage \\\u003C20%, or clinical blood draw not planned",{"count":621,"type":22},300,"This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others.\n\nThe genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.",[30,391,624],"Myeloproliferative Syndrome",[30,391,626],"Myeloproliferative syndrome (MPS)",{"date":607,"type":41},{"date":629,"type":41},"2021-06-11",{"date":631,"type":22},"2033-06",{"name":167,"class":114},8,{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":643,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":663,"locationsCount":49},"100172212","phase-2-cladribine-plus-low-dose-cytarabine-ldac-alternating-with-decitabine-in-patients-with-acute-myeloid-leukemia-aml-or-high-risk-myelodysplastic-syndrome-mds-100172212","NCT01515527","Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","Cohort 1\n\nInclusion Criteria:\n\n1. Patients with previously untreated AML or high risk MDS (\\>\u002F= 10 % blasts or IPSS \\>\u002F= intermediate-2). Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, ATRA, or total dose of cytarabine up to 2g is allowed. Patients with history of MDS transformed to AML are eligible regardless of their prior therapy for MDS provided this will be their first induction therapy for AML.\n2. Age \\>\u002F= 60 years. Patients aged \\\u003C 60 years who are unsuitable for standard induction therapy may be eligible after discussion with PI\n3. Adequate organ function as defined below:\n\n   * liver function (bilirubin \\\u003C 2mg\u002FdL, AST and\u002For ALT \\\u003C3 x ULN)\n   * kidney function (creatinine \\\u003C 1.5 x ULN ).\n4. ECOG performance status of ≤ 2.\n5. A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\n6. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.\n7. Prior therapy with decitabine will be allowed unless the patient experienced progression to AML while being treated with decitabine.\n\nExclusion Criteria:\n\n1. Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.\n2. Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n3. Patient with documented hypersensitivity to any of the components of the chemotherapy program.\n4. Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.\n\nCohort 2\n\nInclusion Criteria:\n\n8\\. Patients with previously untreated AML who are not currently eligible for other frontline clinical trials of AML therapy. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, ATRA, or total dose of cytarabine up to 2g is allowed. Patients with history of MDS transformed to AML are eligible regardless of their prior therapy for MDS provided this will be their first induction therapy for AML.\n\n9\\. Age \\>\u002F= 18 years who are unsuitable for standard induction therapy are eligible after discussion with PI 10. Patients must have one of the following:\n\n* Creatinine \\>\u002F= 2 mg\u002FdL\n* Total bilirubin \\>\u002F= 2 mg\u002FdL\n* ECOG Performance Status equal to 3 or 4\n* Is ineligible for participation in a protocol of higher priority 11. A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\n\n  12\\. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.\n\n  13\\. Prior therapy with decitabine will be allowed unless the patient experienced progression to AML while being treated with decitabine.\n\nExclusion Criteria:\n\n5\\. Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.\n\n6\\. Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, unless these illnesses are judged to be related to the underlying leukemia.\n\n7\\. Patient with documented hypersensitivity to any of the components of the chemotherapy program.\n\n8\\. Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.\n\nCohort 3\n\nInclusion Criteria:\n\n1. Patients with relapsed and or refractory AML who have received at least one prior therapy for their AML.\n2. Age \\>\u002F= 18 years.\n3. Adequate organ function as defined below:\n\n   * liver function (bilirubin \\\u003C 2mg\u002FdL, AST and\u002For ALT \\\u003C3 x ULN)\n   * kidney function (creatinine \\\u003C 1.5 x ULN ).\n4. ECOG performance status of ≤ 2.\n5. A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\n6. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.\n7. Prior therapy with venetoclax will be allowed.\n\n   Exclusion Criteria\n8. Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.\n9. Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n10. Patient with documented hypersensitivity to any of the components of the chemotherapy program.\n\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation",{"count":642,"type":22},160,[25],"The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied.\n\nCladribine is designed to interfere with the cell's ability to process DNA (the genetic material of cells). It can also insert itself into the DNA of cancer cells to stop them from growing and repairing themselves.\n\nCytarabine is designed to insert itself into DNA of cancer cells to stop them from growing and repairing themselves.\n\nDecitabine is designed to damage the DNA of cells, which may cause cancer cells to die.\n\nThis is an investigational study. Cladribine is FDA approved and commercially available for use in patients with hairy cell leukemia. Its use in patients with AML is investigational.\n\nCytarabine is FDA approved and commercially available for use in patients with AML.\n\nDecitabine is FDA approved and commercially available for use in patients with MDS. Its use for patients with AML is investigational.\n\nUp to 160 patients will take part in this study. All will be enrolled at MD Anderson.",[30],[30,647,64,648,286,649,650,651,652,653,654,655,656,657,658],"Acute myeloid leukemia","myelodysplastic syndrome","Cytarabine","Ara-C","Cytosar","DepoCyt","Cytosine Arabinosine Hydrochloride","Decitabine","Dacogen","Cladribine","Leustatin","2-CdA",{"date":607,"type":41},{"date":661,"type":41},"2012-02-07",{"date":532,"type":22},{"name":452,"class":114},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":673,"briefSummary":674,"conditions":675,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":4},"100645643","phase-2-dexamethasone-intravenous-injection-of-human-immunoglobulin-and-increased-infusion-of-mononuclear-cells-to-reduce-donor-specific-antibodies-in-haploidentical-hematopoietic-stem-cell-transplantation-100645643","NCT07698080","Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation","Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploid Hematopoietic Stem Cell Transplantation: a Prospective, Multicenter Study","Inclusion Criteria:\n\n1. Diagnosis of benign or malignant hematological diseases (including leukemia, lymphoma, thalassemia, aplastic anemia, myelodysplastic syndromes, etc.) confirmed by NCCN guidelines, and determined by the investigator to require allogeneic hematopoietic stem cell transplantation.\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n3. Donor-specific antibody (DSA) mean fluorescence intensity (MFI) \\> 500.\n4. Age between 18 and 65 years (age limits are also captured separately in the eligibility module).\n5. Body weight between 40 kg and 100 kg.\n6. No other suitable donor available (i.e., no DSA-negative related donor or unrelated donor).\n\nExclusion Criteria:\n\n1. Patients unsuitable for transplantation or without willingness to undergo transplantation, or diagnosed with non-hematological diseases.\n2. Estimated life expectancy \\\u003C 1 month.\n3. Known allergy to any drug or intervention used in the study regimen.\n4. Pregnancy, lactation, active severe infection, or severe major organ dysfunction.\n5. Severe psychiatric or neurological disorders that may affect the ability to provide informed consent and\u002For to report adverse events or comply with observation.\n6. Refusal or inability to sign the informed consent form.","65 Years",{"count":125,"type":22},[25],"This study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (DSA) in patients who need a stem cell transplant from a half-matched (haploidentical) family donor.\n\nIn these transplants, DSA are antibodies made by the patient's own body that attack the donor's stem cells. If DSA levels are high, the transplant is more likely to fail - the donor cells may not \"take\" (engraft). Currently, there is no single, simple, and reliable way to reduce DSA, and many existing methods have drawbacks.\n\nBased on the investigators' earlier experience in 11 patients, this three-part approach seemed to work well. All patients successfully engrafted, and DSA levels dropped quickly. Now the study team want to confirm these results in a larger, prospective, multicenter study.\n\nThe investigators plan to enroll 60 patients aged 18-65 with blood cancers or other blood disorders who need a haploidentical transplant, have DSA levels above 500 MFI (a measure of antibody strength), and have no other suitable donor available. Participants will receive:\n\n* Dexamethasone (25 mg\u002Fm²) for 4 days before transplant,\n* IVIG (1 g\u002Fkg) one day before transplant,\n* Extra mononuclear cells on transplant day - the extra amount depends on how high their DSA level is (low, medium, or high).\n\nThe main goal is to see how many patients have primary graft failure (when the donor cells never engraft). The study team will also measure how long it takes for blood counts to recover, rates of graft-versus-host disease, survival, and side effects. All participants will be followed for 1 year.\n\nThis study will help the investigators find out whether this combination is a safe, simple, and effective way to improve transplant success for patients with DSA who have no other donor options.",[30,31,676,677,391],"Thalassemia","Aplastic Anemia","2026-07-11",{"date":680,"type":41},"2026-07-14",{"date":682,"type":22},"2026-07-03",{"date":684,"type":22},"2028-07-03",{"name":686,"class":114},"Hematology department of the 920th hospital"]